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ABSTRACT
Background: We previously built a pollen challenge test unit (allergen challenge chamber: ACC) to collect ob-
jective data about Japanese cedar pollinosis. In this study, we investigated adequate conditions for pollen chal-
lenge using the ACC.
Methods: The study consisted of two parts. The first part was conducted in November, which is not in pollen
season. Subjects were exposed to Japanese cedar pollen at a concentration of 50,000 grainsm3 in the cham-
ber for 120 min each day over the course of three consecutive days. The second part was conducted in April,
which is just after pollen season. Subjects were exposed to Japanese cedar pollen at the same concentration
(50,000 grainsm3) in the chamber for 90 min on a single day. Subjects recorded nasal and ocular symptoms
before challenge and every 15 min after challenge initiation. The minimum cross-sectional area in the nasal
cavity was measured using acoustic rhinometry before and after challenge as an indicator of nasal obstruction.
Inflammatory markers in nasal lavage fluid and serum were also measured before and after challenge.
Results: Nasal and ocular symptoms were significantly exacerbated after challenge on all days of the single
and 3-consecutive-day challenge tests, particularly on the third day of the consecutive challenge test. Nasal
and ocular symptoms were also quickly induced with challenge immediately after the end of pollen season. No
significant changes in inflammatory markers were seen.
Conclusions: Care is needed with regard to pollen challenge conditions in the ACC, including timing of the
challenge, to induce pollinosis symptoms that accurately reflect chronic inflammation.
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INTRODUCTION
The prevalence of cedar pollinosis has steadily in-
creased in Japan, reaching 30% in some regions and
age groups.1 Although pollinosis is not life threaten-
ing, it markedly reduces quality of life and productiv-
ity,2-5 leading to both economic and social problems.
Many clinical studies evaluating the effects of ce-
dar pollinosis have used placebo-controlled double-
blind methodology and field techniques involving ce-
dar pollinosis patients.6,7 However, in this sort of
study, the accuracy of evaluation may be hampered
by variations in pollen count and climatic conditions
between years and regions.
Accurate induction tests and evaluation of the phar-
macological effects of drugs require objective obser-
vation and the maintenance of identical conditions
during pollen challenge. These requirements can be
met using an allergen challenge chamber (ACC).
Such controlled chambers, allowing the acquisition of
objective data, have been established in Western
countries and Japan.8-10
We established an ACC in Osaka in 2005, and have
conducted pollen exposure trials under various condi-
tions using this chamber. We found that the temporal
and spatial variations of the pollen level in the ACC
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were small, facilitating stable pollen challenge, and
that pollinosis symptoms could be induced in volun-
teers with cedar pollinosis.
However, sensitivity to antigens is known to be
higher in the latter part of the pollen season as a re-
sult of the priming effect from repeated exposure to
antigens.11 Therefore, to induce symptoms that
match those occurring in real life, we must also con-
sider the effects of when the trial is actually con-
ducted. In trials that use a pollen challenge chamber
during non-pollen seasons, the absence of this prim-
ing effect cannot be ignored and appropriate pollen
exposure conditions need to be established.
Using volunteers with cedar pollinosis as subjects,
we compared the induction of symptoms using the
ACC immediately after the end of pollen season and
during the non-pollen season.
METHODS
The ACC system consists of a challenge chamber in
which subjects are actually exposed to pollen, a ma-
chine room to prepare pollen, an air shower room to
remove pollen on leaving the challenge chamber, a
consultation room in which a physician examines the
patient regarding symptoms, a test room for objective
testing, a changing room for patients to change into a
clean suit, and a waiting room in which the test is ex-
plained to patients. The area and ceiling height of the
challenge chamber are approximately 21.8 m2 and 2.5
m, respectively, with a maximum capacity of 12 peo-
ple. Patients in the challenge chamber can be ob-
served through a one-way mirror. The challenge
chamber is controlled at a constant temperature
(summer: 25 ± 3℃, winter: 23 ± 3℃) and relative hu-
midity (summer: 50 ± 10%, winter: 45 ± 10%) using an
external air-processing air conditioner, and it can be
ventilated with clean air from which dust is removed
using a high-performance filter (HEPA filter). Em-
ploying a cylinder feeder-type powdering device
(Aerosol generator RBG-1000R; Palas Co., NJ, USA),
cedar pollen was dispersed during the tests into the
compressed air supply while controlling the level,
and homogenously sprayed in the challenge chamber
via 12 Anemostat-type diffusers installed in the ceil-
ing. The pollen level was determined by the aspira-
tion method, measuring aspirated particles using a
light-scattering particle counter for gross particles
(KC-20; Rion Co., Ltd., Tokyo, Japan). Pollen in the
challenge chamber can be removed through a filter
box. The pollen level in the challenge chamber was
secondarily diluted by adjusting the ventilation level
of the outside air-processing air conditioner. The pol-
len level was adjusted to a specified level within about
20 minutes, and the maintenance level was adjusted
corresponding to the real-time measured level (every
4 minutes). The ceiling and walls are finished with
antistatic cloth to avoid the adherence of sprayed pol-
len.
SUBJECTS AND ASSESSMENTS
Subjects comprised 9 men and 23 women (mean age,
29.7 ± 1.09; range, 20-42 years) with mild or severe
cedar pollinosis symptoms. All subjects had a clinical
history of Japanese cedar pollinosis and scores of 2 or
more for Japanese cedar pollen on the CAP ra-
dioallergosorbent test (CAP-RAST), which is the
most commonly used test to measure allergen spe-
cific IgE levels in sera. Individuals with significant
anatomic abnormalities on nasal examination were
excluded.
The study consisted of two parts. In the first part,
conducted in November, which is not in pollen sea-
son, subjects were exposed to Japanese cedar pollen
at a concentration of 50,000 grainsm3 in the cham-
ber for 120 min per day over the course of three con-
secutive days. In the second part, conducted in April,
just after pollen season, subjects were exposed to
Japanese cedar pollen at the same concentration
(50,000 grainsm3) for 90 min on a single day. Four
men and nine women were enrolled in the first part of
study and five men and sixteen women were enrolled
in the second part of study. Two subjects participated
in both studies.
Nasal and ocular symptoms (sneezing frequency,
nose-blowing frequency, nasal obstruction, and ocu-
lar itching) were recorded before challenge and
every 15 min after challenge initiation. For the evalu-
ation of nasal obstruction and ocular itch, we used
visual analog scales (VASs); subjects marked a site
on a 10-cm line corresponding to the symptom sever-
ity on which absence of symptoms was designated as
0 and worst imaginable symptoms as 10. To objec-
tively evaluate nasal obstruction, the minimum cross-
sectional area of the nasal cavity was also measured
using acoustic rhinometry (SRE2100 Rhino Metrics,
Lynge, Denmark) before and after challenge.
NASAL LAVAGE AND SAMPLE PROCESSING
The nasal lavage was performed by instilling 5 ml of
sterile saline to each nostril according to the previous
report.12 To increase cell viability, sample processing
was kept at 4℃. The serum was drawn subsequently,
and the nasal lavage fluids and sera were separated
from cells by a centrifugation at 1,500 x g to be stored
frozen until analysis.
MEDIATOR ASSAYS
The level of ECP, IFN-γ, total IgE and specific IgE
were measured by enzyme immunoassay (EIA; SRL
Inc., Tokyo, Japan). IL-4 concentration was measured
by chemiluminescent enzyme assay (CLEIA; SRL
Inc.). IL-5 concentration was measured by Enzyme-
Linked immunosorbent assay (ELISA; SRL Inc.).
Anti-allergy medications such as anti-histamines and
steroid sprays were prohibited for one week before
the trial, and people receiving desensitization therapy
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were excluded.
The study was conducted in accordance with Good
Clinical Practice (GCP) guidelines and the Declara-
tion of Helsinki. The study protocol was reviewed and
approved by the Research Committee at Osaka Medi-
cal College. Informed consent was obtained from all
subjects prior to study entry. Data were anonymously
processed during analysis.
STATISTICAL ANALYSIS
Wilcoxon single-rank test was used to analyze symp-
tom scores and VAS scores in each group. Results
were expressed as the change from the score before
pollen exposure.
RESULTS
SYMPTOM INDUCTION TEST IN THE NON-
POLLEN SEASON
Changes in symptoms were investigated before and
after challenges on three consecutive days. Changes
in the four symptoms (sneezing frequency, nose-
blowing frequency, nasal obstruction, and ocular itch-
ing) are shown in Figure 1. No significant symptoms
were induced on the first day of challenge in the non-
pollen season. However, each of the four symptoms
became more severe with each day of challenge, and
a significant increase was seen in cumulative values
by the third day.
SYMPTOM INDUCTION TEST IMMEDIATELY AF-
TER POLLEN SEASON (Fig. 2)
Immediately after pollen season, significant symp-
toms were induced quickly, 15 min after the start of
exposure.
No adverse events were observed during the
course of these studies, and none of the subject used
anti-allergy medicine during the test periods.
ACOUSTIC RHINOMETRY ANALYSIS (Fig. 3)
Significant decreases were seen in minimum cross-
sectional area in the nasal cavity on the third day of
challenge in the non-pollen season and after the sin-
gle challenge immediately after the pollen season.
CHANGES IN EOSINOPHILIC LEUKOCYTE CO-
UNT IN NASAL LAVAGE FLUID BEFORE AND
AFTER CHALLENGE
The eosinophilic leukocyte count in nasal lavage fluid
tended to be higher on the third day of exposure than
on the first and second days, but this difference was
not significant. No changes were seen before and af-
ter exposure in terms of eosinophil cationic protein
(ECP), interleukin (IL)-4, IL-5, or interferon (IFN)-γ
in nasal lavage fluid, total IgE in peripheral blood, or
IgE specific to Japanese cedar pollen, ECP, IL-4, or
IL-5 (data not shown).
DISCUSSION
Conducting the present study in our ACC offered
scheduling advantages independent of pollen expo-
sure season, although the results suggest that prim-
ing effect should not be overlooked in ACC studies.
Traditional seasonal allergic rhinitis trials are per-
formed for up to several weeks during the pollen sea-
son. However, a number of variables, including differ-
ences in pollen levels over the course of the study,
subject compliance, and recall bias, reduce the sensi-
tivity of these trials. When trials are conducted in
multiple locations, some of these variations may be
exaggerated and make adjusting for differences
much more difficult. These factors contribute to lack
of sensitivity for detecting differences between treat-
ments in terms of onset and duration of action, or dif-
ferences between various doses of the same treat-
ment. This is one reason why onset of action is an
endpoint that is difficult to monitor in traditional stud-
ies and why it is rarely measured. Use of an ACC can
overcome many of the problems associated with tra-
ditional trials.
ACCs were initially established in the 1980s,13 and
the first clinical report using an ACC was published
in 1988.14 There are only limited numbers of effective
ACCs worldwide because a system capable of strictly
controlling antigen particles is necessary. One condi-
tion required is the capability to maintain a specific
pollen level for a certain period. It is also necessary to
induce moderate to severe nasal allergy symptoms in
allergic subjects while inducing no symptoms in non-
allergic subjects.15 To meet the increased needs for
such facilities, the first ACC in Japan was developed
in Wakayama in April 2005. We built a second ACC in
Osaka in September 2005. The pollen level in the
challenge chamber is secondarily diluted by adjust-
ing the ventilation level of the outside air-processing
air conditioner. The pollen level is adjusted to a speci-
fied level within approximately 20 min, and the main-
tenance level is adjusted corresponding to the actual
level measured in real time (every 4 min).
Using an ACC, seasonal allergic rhinitis studies
may be conducted both in and out of the pollen sea-
son. In-season studies allow control of many factors
that cannot be regulated with traditional trial method-
ology. Additionally, less priming is required than in
out-of-season studies, particularly for subjects who
are already symptomatic. The reactivity of an allergic
individual to a seasonal allergen should increase dur-
ing the season because of the priming effect.11 It is ar-
gued that the reactivity of participants to allergens in
an ACC setting may differ from that observed in a
natural environment.16 In the present trial, we found
that symptoms were induced more rapidly after the
end of pollen season than with out-of-season expo-
sure. With the 3-consecutive-day challenge in the
non-pollen season, the severity of symptoms was
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Fig.　1　Changes in symptoms after challenge initiation were investigated in 3-consecutive-day challenge tests. 
Four items, (A) sneezing frequency and nose-blowing frequency, (B) nasal obstruction and ocular itching, were 
signifi cantly exacerbated after challenge on the third day of the consecutive challenge test.
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Fig.　2　Changes in the symptoms after challenge initiation were investigated in a single-day chal-
lenge test. Nasal obstruction and itch were signifi cantly exacerbated after the challenge test. The 
four symptoms (sneezing frequency, nose-blowing frequency, nasal obstruction, and ocular itch-
ing) increased signifi cantly compared with before the challenge after 15 min of pollen dispersal.
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Fig.　3　Changes in minimum cross-sectional area of the nasal cavity measured with acoustic rhinometry. 
(A) Three-consecutive-day challenge during non-pollen season. (B) Single-day challenge immediately af-
ter the end of pollen season.
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seen to increase proportionally with the number of
days of challenge. These findings show a priming ef-
fect and may be influenced by a late phase reaction.
Nasal allergy symptoms from challenge immediately
after the end of pollen season are thought to be close
to pollinosis symptoms in a natural environment.
However, there are also influences from the regional
and annual differences in the amount of pollen re-
leased into the air, and findings may differ from those
with an ACC, which operates on the supposition of in-
ducing symptoms under uniform conditions.
There are several ACCs in Japan. However, it is dif-
ficult to accurately compare the results obtained be-
tween units, because each chamber uses a different
method to count pollen grains. Our ACC uses the KC-
20, a laser particle counter which measures the num-
ber of particles between 10 and 100 μm in diameter.
We attempted measurements with the KC-20 and the
Durham method and the pollen counts measured by
these two methods were well correlated. The pollen
level in the chamber, 50,000 grainsm3, corre-
sponded to approximately 10 times the maximum
count in the pollen-scattering season. There is a dif-
ference in the number of pollen that induces nasal
symptoms observed in our ACC and in studies con-
ducted in the natural environment. The priming effect
of repeated antigen challenge increases sensitivity to
the antigen in a natural environment.16
In recent years, pollinosis resulting from a single
antigen has been decreasing and that from multiple
antigens has been on the rise. Because a number of
allergens and environmental factors may contribute
to developing rhinitis, it has been argued that the sin-
gle allergen exposure that is typically used in an ACC
setting may not reflect the natural pathological proc-
ess.17 The degree of exposure to other sensitizing al-
lergens is variable, since the level of previous envi-
ronmental exposure cannot be controlled. Priming is
a complex process that occurs naturally and in the
ACC setting, and manifests as typical allergy symp-
toms.
Clinical trials using an ACC are suitable for scien-
tific evaluations of various treatments for cedar polli-
nosis, but effective measurements and evaluation
items other than clinical symptoms have not yet been
identified. In the present study, no significant
changes were seen in eosinophilic leukocyte count,
ECP, IL-4, IL-5, or IFN-γ in nasal lavage fluid, or in to-
tal IgE and cedar pollen specific IgE, ECP, IL-4, or IL-
5 in peripheral blood. Although allergy symptoms can
be induced, it may not be possible to adequately in-
duce chronic allergic inflammation in an ACC setting.
To induce allergic rhinitis symptoms in the form of
chronic allergic inflammation without priming from
the natural environment, medium- to long-term con-
tinuous challenge during the non-pollen season is
thought to be necessary, rather than the short-term
challenge performed in the present study. This is not
easy, however, because of social restrictions on vol-
unteers. In future studies, it may be necessary to in-
duce symptoms with short-term challenge while si-
multaneously identifying elevated the kind of mRNA
in nasal lavage fluid and peripheral blood.
In conclusion, using an allergen challenge cham-
ber, pollinosis symptoms, such as nasal and ocular
symptoms, could be induced with good reproducibil-
ity even immediately after the end of the pollen sea-
son and in the non-pollen season, but differences
were seen in the conditions required to induce symp-
toms. Although somewhat difficult from a practical
standpoint, induction of pollinosis symptoms reflect-
ing chronic allergic inflammation is thought to re-
quire medium- to long-term continuous challenge
during the non-pollen season.
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